Format

Send to

Choose Destination
Clin Immunol. 2017 Mar;176:63-70. doi: 10.1016/j.clim.2016.12.003. Epub 2016 Dec 24.

Doxorubicin enhances the capacity of B cells to activate T cells in urothelial urinary bladder cancer.

Author information

1
Department of Medicine, Unit of Immunology and Allergy, Karolinska Institutet, Stockholm, Sweden.
2
Department of Surgical and Perioperative Sciences, Urology and Andrology, Umeå University Hospital, Umeå, Sweden; Department of Urology, Stockholm South General Hospital, Karolinska Institutet, Stockholm, Sweden.
3
Department of Urology, Sundsvall Hospital, Sundsvall, Sweden.
4
Department of Urology, Akademiska University Hospital, Uppsala, Sweden.
5
Centre for Research and Development, Faculty of Medicine, Uppsala University, County Council of Gävleborg, Uppsala, Sweden.
6
Department of Urology, Länssjukhuset Ryhov, Region Jönköping, Sweden.
7
Department of Medical Biosciences, Pathology, Umeå University, Umeå, Sweden.
8
Department of Surgical and Perioperative Sciences, Urology and Andrology, Umeå University Hospital, Umeå, Sweden.
9
Department of Medicine, Unit of Immunology and Allergy, Karolinska Institutet, Stockholm, Sweden. Electronic address: ola.winqvist@karolinska.se.

Abstract

Cancer is currently treated by a combination of therapies, including chemotherapy which is believed to suppress the immune system. Combination of immunotherapy and chemotherapy correlates with improved survival but needs careful planning in order to achieve a synergistic effect. In this study, we have demonstrated that doxorubicin treatment of B cells resulted in increased expression of CD86 and concordantly increased CD4+ T cell activation in the presence of superantigen, an effect that was inhibited by the addition of a CD86 blocking antibody. Furthermore, doxorubicin resulted in decreased expression of the anti-inflammatory cytokines IL-10 and TNF-α. Finally, B cells from urinary bladder cancer patients, treated with a neoadjuvant regiment containing doxorubicin, displayed increased CD86-expression. We conclude that doxorubicin induces CD86 expression on B cells and hence enhances their antigen-presenting ability in vitro, a finding verified in patients. Development of tailored time and dose schedules may increase the effectiveness of combining chemotherapy and immunotherapy.

KEYWORDS:

B cells; CD86; Doxorubicin; Immunology; Neoadjuvant chemotherapy; Urinary bladder cancer

PMID:
28025135
DOI:
10.1016/j.clim.2016.12.003
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center